Download our technical case study on integrating high-confidence sequencing with optimized transient CHO expression to de-risk your bsAb pipeline.
The structural complexity of bispecific antibodies (bsAbs) introduces significant risks in yield, stability, and correct pairing. Avoiding late-stage failures requires an integrated approach starting at the sequence level.
In this collaboration with Rapid Novor, we demonstrate a proven workflow for translating complex designs into high-yield prototypes. By combining high-confidence monoclonal antibody sequencing with evitria’s industry-leading transient CHO expression platform, researchers can achieve full sequence certainty and the delivery of purified protein in as little as four weeks.
Technical Insights Included:
- Sequence Integrity: How to eliminate the ‘1% error’ that compromises bispecific assembly.
- Production Speed: Delivering developable leads from sequence to shipping in record time.
- Format Flexibility: Data on pairing success for DuoBody®, IgG-scFv, and asymmetric formats.
- Expert Webinar: On-demand access to the joint technical session with Rapid Novor and evitria specialists.
Request the Case Study & Webinar Recording!
